ReachMD

Episodes 1-11 of 11

• • 

    

    Edward Chu, MD

    Peer

  • 

    

    Michael J. Overman, MD

    Peer

  6

  

  RestartResume

  Keeping Pace in GI Cancer: Advances in Immunotherapy in MSI-H/dMMR Metastatic Colorectal Cancer

  Keeping Pace in GI Cancer: Advances in Immunotherapy in MSI-H/dMMR Metastatic Colorectal Cancer

  0.25 credits

• • 

    

    Scott Kopetz, MD, PhD

    Peer

  • 

    

    Prof Eric Van Cutsem, MD, PhD

    Peer

  • 

    

    Josep Tabernero, MD, PhD

    Peer

  8

  

  RestartResume

  Optimizing Treatment Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer

  Optimizing Treatment Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer

  0.25 credits

• • 

    

    Richard T. Penson, MD, MRCP

    Peer

  • 

    

    Linda R. Duska, MD, MPH

    Peer

  16

  

  RestartResume

  Keeping Pace in Women’s Cancer: Focus on Endometrial Carcinoma

  Keeping Pace in Women’s Cancer: Focus on Endometrial Carcinoma

  0.25 credits

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Alexander Drilon, MD

    Peer

  11

  

  RestartResume

  Keeping Pace: Advances in RET Fusion-Positive NSCLC

  Keeping Pace: Advances in RET Fusion-Positive NSCLC

  0.25 credits

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Helena Yu, MD

    Peer

  8

  

  RestartResume

  Keeping Pace: Advances in First-Line Therapy for EGFR-mutated NSCLC

  Keeping Pace: Advances in First-Line Therapy for EGFR-mutated NSCLC

  0.25 credits

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Gilberto de Lima Lopes Junior, MD, MBA, FAMS

    Peer

  5

  

  RestartResume

  Keeping Pace: The Use of Immunotherapy in Mutation-Positive Non-Small Cell Lung Cancer

  Keeping Pace: The Use of Immunotherapy in Mutation-Positive Non-Small Cell Lung Cancer

  0.25 credits

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Edward B. Garon, MD, MS

    Peer

  4

  

  RestartResume

  Keeping Pace: The Role of Immunotherapy After Disease Progression

  Keeping Pace: The Role of Immunotherapy After Disease Progression

  0.25 credits

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Suresh S. Ramalingam, MD

    Peer

  8

  

  RestartResume

  Keeping Pace: The Role of Immunotherapy in the Frontline Setting

  Keeping Pace: The Role of Immunotherapy in the Frontline Setting

  0.25 credits

• • 

    

    Warner K. Huh, MD

    Peer

  • 

    

    Deborah K. Armstrong, MD

    Peer

  • 

    

    Robert L. Coleman, MD, FACOG, FACS

    Peer

  14

  

  RestartResume

  Keeping Pace in Women's Cancer: The Role of PARP Inhibitors in Ovarian Cancer

  Keeping Pace in Women's Cancer: The Role of PARP Inhibitors in Ovarian Cancer

  0.25 credits

• • 

    

    Javier Cortes, MD, PhD

    Peer

  • 

    

    Giuseppe Curigliano, MD, PhD

    Peer

  • 

    

    Peter Schmid, FRCP, MD, PhD

    Peer

  0

  

  RestartResume

  Real-World Evidence and Clinical Decision-Making for HR-positive/HER2-negative Metastatic Breast Cancer

  Real-World Evidence and Clinical Decision-Making for HR-positive/HER2-negative Metastatic Breast Cancer

  0.25 credits

• • 

    

    Peter H. O'Donnell, MD

    Peer

  • 

    

    Daniel P. Petrylak, MD

    Peer

  14

  

  RestartResume

  Keeping Pace: Emerging Treatment Considerations in Metastatic Urothelial Cancer

  Keeping Pace: Emerging Treatment Considerations in Metastatic Urothelial Cancer

  0.25 credits